Early Access

10-QPeriod: Q1 FY2022

UNITEDHEALTH GROUP INC Quarterly Report for Q1 Ended Mar 31, 2022

Filed May 4, 2022For Securities:UNH

Summary

UnitedHealth Group (UNH) reported a solid first quarter for 2022, demonstrating continued revenue growth and operational strength. Total revenues increased by 14% year-over-year, reaching $80.1 billion, driven by strong performance across both the UnitedHealthcare and Optum segments. UnitedHealthcare saw a 14% revenue increase, largely fueled by growth in Medicare Advantage and Medicaid programs, serving nearly 1.5 million more people. The Optum segment also delivered robust growth, with revenues up 19%, highlighting the success of its health services, insights, and pharmacy care operations. While net earnings saw a modest increase of 3% to $5.03 billion ($5.27 diluted EPS), the company's operational execution remains a key positive. The company continued its strategic capital allocation, repurchasing $2.5 billion in stock and paying $1.4 billion in dividends. Looking ahead, UNH is progressing with significant acquisitions, including Change Healthcare and LHC Group, which are expected to further enhance its market position and service offerings pending regulatory approvals. The company's balance sheet remains strong, with substantial cash and investments, providing flexibility for future growth and shareholder returns.

Financial Statements
Beta
Revenue$80.15B
Cost of Revenue$8.49B
Gross Profit$71.66B
SG&A Expenses$11.40B
Operating Expenses$73.20B
Operating Income$6.95B
Interest Expense$433.00M
Net Income$5.03B
EPS (Basic)$5.34
EPS (Diluted)$5.27
Shares Outstanding (Basic)941.00M
Shares Outstanding (Diluted)954.00M

Key Highlights

  • 1Consolidated revenues increased by 14% to $80.1 billion, driven by 14% growth in UnitedHealthcare and 19% growth in Optum.
  • 2UnitedHealthcare experienced significant member growth, serving nearly 1.5 million more people, particularly in community and senior programs (Medicare Advantage and Medicaid).
  • 3Optum Health, Insight, and Rx segments all reported strong revenue increases, showcasing diversification and synergistic growth.
  • 4Diluted Earnings Per Share (EPS) grew 4% to $5.27 compared to the prior year's first quarter.
  • 5The company actively returned capital to shareholders through $2.5 billion in share repurchases and $1.4 billion in dividends paid during the quarter.
  • 6Significant strategic acquisitions, including Change Healthcare and LHC Group, are underway, pending regulatory approval, signaling continued expansion efforts.
  • 7Strong operating cash flow of $5.3 billion was generated, supporting business investments and capital returns.

Frequently Asked Questions